Cardiovascular safety of mirabegron: analysis of an integrated clinical trial database of patients with overactive bladder syndrome
Mirabegron is a β3-adrenoreceptor agonist used for the treatment of overactive bladder syndrome. We evaluated the cardiovascular safety of mirabegron using pooled data from 13 studies. The analysis included 13,396 patients who received ≥1 dose of mirabegron (25 mg/50 mg) or comparator antimuscarinics (solifenaci n 2.5 mg/5 mg/10 mg or tolterodine extended release 4 mg) as monotherapies, or placebo. We focused on changes in blood pressure and cardiovascular adverse events. Baseline cardiovascular risk factors had an imbalanced effect on subsequent cardiovascular adverse events.
Source: Journal of the American Society of Hypertension - Category: Cardiology Authors: William B. White, Emad Siddiqui, Tri Tat, Billy Franks, Carol R. Schermer Tags: Research Article Source Type: research
More News: Cardiology | Cardiovascular | Clinical Trials | Databases & Libraries | Heart | Hypertension | Overactive Bladder | Overactive Bladder Syndrome | Study